Compare Stocks: PFE, ABBV, LLY, PAA, and MRK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$285.66 +0.2%	$266.33	$190.75 ▼ $291.40	$503.87B	0.24	5.20 million shs	4.63 million shs
LLY Eli Lilly and Company	$1,275.50 -2.4%	$1,186.64	$809.63 ▼ $1,321.21	$1.23T	0.46	2.30 million shs	2.27 million shs
MRK Merck & Co., Inc.	$145.25 -1.4%	$146.98	$82.01 ▼ $156.92	$363.27B	0.21	9.66 million shs	8.38 million shs
PAA Plains All American Pipeline	$26.63 +2.8%	$25.01	$16.00 ▼ $26.85	$18.27B	0.57	2.26 million shs	3.71 million shs
PFE Pfizer	$30.04 -1.3%	$28.33	$23.62 ▼ $30.44	$173.38B	0.32	29.68 million shs	29.45 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.38%	+0.12%	+7.62%	+10.25%	+24.97%
LLY Eli Lilly and Company	-2.50%	+1.39%	+10.56%	+6.63%	+57.02%
MRK Merck & Co., Inc.	-1.46%	-0.52%	-1.91%	+10.83%	+65.80%
PAA Plains All American Pipeline	+2.82%	+5.47%	+8.96%	+8.25%	+2,662,999,900.00%
PFE Pfizer	-1.18%	+1.56%	+6.65%	+22.47%	+21.53%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$285.66 +0.2%	$266.33	$190.75 ▼ $291.40	$503.87B	0.24	5.20 million shs	4.63 million shs
LLY Eli Lilly and Company	$1,275.50 -2.4%	$1,186.64	$809.63 ▼ $1,321.21	$1.23T	0.46	2.30 million shs	2.27 million shs
MRK Merck & Co., Inc.	$145.25 -1.4%	$146.98	$82.01 ▼ $156.92	$363.27B	0.21	9.66 million shs	8.38 million shs
PAA Plains All American Pipeline	$26.63 +2.8%	$25.01	$16.00 ▼ $26.85	$18.27B	0.57	2.26 million shs	3.71 million shs
PFE Pfizer	$30.04 -1.3%	$28.33	$23.62 ▼ $30.44	$173.38B	0.32	29.68 million shs	29.45 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	+0.38%	+0.12%	+7.62%	+10.25%	+24.97%
LLY Eli Lilly and Company	-2.50%	+1.39%	+10.56%	+6.63%	+57.02%
MRK Merck & Co., Inc.	-1.46%	-0.52%	-1.91%	+10.83%	+65.80%
PAA Plains All American Pipeline	+2.82%	+5.47%	+8.96%	+8.25%	+2,662,999,900.00%
PFE Pfizer	-1.18%	+1.56%	+6.65%	+22.47%	+21.53%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.83	Moderate Buy	$279.86	-2.03% Downside
LLY Eli Lilly and Company	2.86	Moderate Buy	$1,317.93	3.33% Upside
MRK Merck & Co., Inc.	2.59	Moderate Buy	$151.92	4.59% Upside
PAA Plains All American Pipeline	2.44	Hold	$25.87	-2.87% Downside
PFE Pfizer	2.14	Hold	$28.72	-4.37% Downside

Current Analyst Ratings Breakdown

Latest PFE, ABBV, LLY, PAA, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/23/2026	ABBV AbbVie	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$258.00 ➝ $294.00
10/21/2026	LLY Eli Lilly and Company	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$1,309.00 ➝ $1,316.00
10/21/2026	ABBV AbbVie	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$300.00 ➝ $325.00
10/20/2026	LLY Eli Lilly and Company	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$1,413.00
10/19/2026	PAA Plains All American Pipeline	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Strong-Buy	$28.00
10/19/2026	MRK Merck & Co., Inc.	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/15/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Buy (B) ➝ Buy (B+)
10/15/2026	PAA Plains All American Pipeline	Scotiabank Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$28.00
10/14/2026	PAA Plains All American Pipeline	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (A-) ➝ Buy (B+)
10/13/2026	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/13/2026	ABBV AbbVie	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$280.00

(Data available from 10/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$61.16B	8.25	$15.17 per share	18.83	($1.83) per share	-156.10
LLY Eli Lilly and Company	$65.18B	18.42	$24.54 per share	51.98	$28.07 per share	45.44
MRK Merck & Co., Inc.	$66.57B	5.38	$11.27 per share	12.89	$21.22 per share	6.84
PAA Plains All American Pipeline	$44.26B	0.42	$3.36 per share	7.93	$15.65 per share	1.70
PFE Pfizer	$62.58B	2.74	$4.34 per share	6.92	$15.26 per share	1.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.23B	$3.54	80.69	17.79	1.30	9.80%	-422.07%	14.34%	10/30/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	42.80	27.01	1.74	33.53%	97.83%	23.23%	10/29/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$1.25	116.20	15.69	6.83	4.77%	16.73%	6.13%	10/29/2026 (Estimated)
PAA Plains All American Pipeline	$1.44B	$3.61	16.29	14.88	9.17	5.29%	12.13%	4.59%	N/A
PFE Pfizer	$7.77B	$0.76	9.97	10.18	2.07	6.80%	19.63%	8.46%	11/3/2026 (Estimated)

Latest PFE, ABBV, LLY, PAA, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	PFE Pfizer	$0.7280	N/A	N/A	N/A	$15.86 billion	N/A
10/30/2026	Q3 2026	ABBV AbbVie	$3.74	N/A	N/A	N/A	$17.35 billion	N/A
10/29/2026	Q3 2026	LLY Eli Lilly and Company	$5.70	N/A	N/A	N/A	$22.58 billion	N/A
10/29/2026	Q3 2026	MRK Merck & Co., Inc.	$2.09	N/A	N/A	N/A	$17.31 billion	N/A
8/7/2026	Q2 2026	PAA Plains All American Pipeline	$0.50	$0.41	-$0.09	$2.51	N/A	$17.69 billion
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
8/4/2026	Q2 2026	MRK Merck & Co., Inc.	-$0.26	-$0.13	+$0.13	-$0.54	$16.37 billion	$16.61 billion
8/4/2026	Q2 2026	PFE Pfizer	$0.6820	$0.77	+$0.0880	-$0.04	$14.40 billion	$15.03 billion
7/31/2026	Q2 2026	ABBV AbbVie	$3.61	$3.65	+$0.04	$2.03	$16.80 billion	$16.99 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.92	2.42%	+6.80%	195.48%	53 Years
LLY Eli Lilly and Company	$6.92	0.54%	+15.18%	23.22%	11 Years
MRK Merck & Co., Inc.	$3.40	2.34%	+5.75%	272.00%	14 Years
PAA Plains All American Pipeline	$1.67	6.27%	+11.05%	46.26%	5 Years
PFE Pfizer	$1.72	5.73%	-13.20%	226.32%	16 Years

Latest PFE, ABBV, LLY, PAA, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/6/2026	PFE Pfizer	quarterly	$0.43	6.26%	11/6/2026	11/6/2026	12/7/2026
9/10/2026	ABBV AbbVie	quarterly	$1.73	2.44%	10/15/2026	10/15/2026	11/16/2026
10/1/2026	PAA Plains All American Pipeline	quarterly	$0.4175	7.06%	10/30/2026	10/30/2026	11/13/2026
7/29/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.36%	9/15/2026	9/15/2026	10/7/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	N/A	0.81	0.69
LLY Eli Lilly and Company	1.41	1.35	1.00
MRK Merck & Co., Inc.	1.22	1.32	1.10
PAA Plains All American Pipeline	0.69	1.12	1.10
PFE Pfizer	0.71	1.27	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
PAA Plains All American Pipeline	41.78%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.06%
LLY Eli Lilly and Company	0.14%
MRK Merck & Co., Inc.	0.17%
PAA Plains All American Pipeline	1.07%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	57,000	1.77 billion	1.77 billion	Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.46 billion	Optionable
PAA Plains All American Pipeline	3,900	705.57 million	698.02 million	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

PFE, ABBV, LLY, PAA, and MRK Headlines

Recent News About These Companies

Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem

3 hours ago | fool.com

Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem

3 hours ago | fool.com

Is Pfizer (PFE) Cheap As Its Enodia Deal Fuels Oncology Growth Hopes?

October 23 at 8:38 PM | finance.yahoo.com

Pfizer (NYSE:PFE) Shares Down 1.3% - Should You Sell?

October 23 at 5:20 PM | marketbeat.com

Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

October 23 at 9:30 AM | 247wallst.com

Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

October 23 at 9:17 AM | 247wallst.com

3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach (PFE)

...

October 23 at 7:25 AM | marketbeat.com

Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?

October 23 at 6:11 AM | fool.com

Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?

October 23 at 5:43 AM | fool.com

What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer

October 22 at 8:31 PM | fool.com

What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer

October 22 at 8:00 PM | fool.com

Pfizer (NYSE:PFE) Shares Climb 1.8% - Still a Buy?

October 22 at 7:39 PM | marketbeat.com

Bristol Myers Squibb vs. Pfizer: Consistency vs.

October 22 at 5:25 PM | fool.com

Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher

October 22 at 2:11 PM | 247wallst.com

Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher

October 22 at 1:55 PM | 247wallst.com

Pfizer’s PF-07999415 Trial Reaches Phase 1 Finish Line, Offering Fresh Clues for Pipeline Value

October 22 at 12:31 PM | tipranks.com

Pfizer’s Swedish Ibrance Study Offers Fresh Real‑World Signals for PFE Investors

October 22 at 12:31 PM | tipranks.com

Pfizer’s High Dividend Yield May Be a Warning. Here’s How Merck Compares

October 22 at 12:31 PM | 247wallst.com

Pfizer's High Dividend Yield May Be a Warning. Here's How Merck Compares

October 22 at 12:15 PM | 247wallst.com

PFE:CA Balance Sheet

October 22 at 7:35 AM | seekingalpha.com

Pfizer (PFE) Signs New Drug Discovery Pact Focused On Sec61 Inhibitors

October 22 at 1:04 AM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PFE, ABBV, LLY, PAA, and MRK Company Descriptions

AbbVie NYSE:ABBV

$285.66 +0.47 (+0.16%)

Closing price 10/23/2026 03:59 PM Eastern

Extended Trading

$285.27 -0.39 (-0.14%)

As of 10/23/2026 07:56 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Eli Lilly and Company NYSE:LLY

$1,275.50 -31.19 (-2.39%)

Closing price 10/23/2026 03:59 PM Eastern

Extended Trading

$1,278.93 +3.43 (+0.27%)

As of 10/23/2026 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$145.25 -1.99 (-1.35%)

Closing price 10/23/2026 03:59 PM Eastern

Extended Trading

$145.40 +0.15 (+0.10%)

As of 10/23/2026 08:00 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Plains All American Pipeline NASDAQ:PAA

$26.63 +0.73 (+2.82%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$26.67 +0.04 (+0.17%)

As of 10/23/2026 07:56 PM Eastern

Plains All American Pipeline, L.P., through its subsidiaries, engages in the pipeline transportation, terminalling, storage, and gathering of crude oil and natural gas liquids (NGL) in the United States and Canada. The company operates in two segments, Crude Oil and NGL. The Crude Oil segment offers gathering and transporting crude oil through pipelines, gathering systems, trucks, and at times on barges or railcars. This segment provides terminalling, storage, and other facilities-related services, as well as merchant activities. As of December 31, 2021, this segment owned and leased 18,300 miles of active crude oil transportation pipelines and gathering systems, as well as an additional 110 miles of pipelines that supports crude oil storage and terminalling facilities; 74 million barrels of commercial crude oil storage capacity; 38 million barrels of active, above-ground tank capacity; four marine facilities; a condensate processing facility; seven crude oil rail terminals and 2,100 crude oil railcars; and 640 trucks and 1,275 trailers. The Natural Gas Liquids segment engages in the natural gas processing, NGL fractionation, storage, transportation, and terminalling activities. As of December 31, 2021, this segment owned and operated four natural gas processing plants; nine fractionation plants; 28 million barrels of NGL storage capacity; approximately 1,620 miles of active NGL transportation pipelines, as well as an additional 55 miles of pipeline that supports NGL storage facilities; 16 NGL rail terminals and approximately 3,900 NGL rail cars; and approximately 220 trailers. The company was founded in 1981 and is headquartered in Houston, Texas.

Pfizer NYSE:PFE

$30.04 -0.39 (-1.27%)

Closing price 10/23/2026 03:59 PM Eastern

Extended Trading

$30.02 -0.01 (-0.04%)

As of 10/23/2026 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, ABBV, LLY, PAA, and MRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, ABBV, LLY, PAA, and MRK Earnings

Compare Dividends

Latest PFE, ABBV, LLY, PAA, and MRK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, ABBV, LLY, PAA, and MRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PFE, ABBV, LLY, PAA, and MRK Company Descriptions

AbbVie NYSE:ABBV

Eli Lilly and Company NYSE:LLY

Merck & Co., Inc. NYSE:MRK

Plains All American Pipeline NASDAQ:PAA

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools